Evotec SE stock rebounds 5.75% on Xetra amid biotech volatility and partnership progress

Evotec SE (ISIN: DE0005664809) shares surged 5.75% to 4.356 EUR on Xetra, signaling stabilization after preliminary 2025 results miss. US investors eye BMS collaborations and AI-driven discovery for exposure to German biotech without direct development risks.

Evotec SE stock climbed 5.75% to 4.356 EUR on Xetra on March 25, 2026, rebounding from a sharp selloff triggered by preliminary 2025 results that missed expectations. The German drug discovery firm's revenue rose 5% year-over-year to about €820 million, short of the €850 million consensus due to delayed milestones and softer fee-for-service billing. For US investors, this volatility highlights entry opportunities into partnerships with giants like Bristol Myers Squibb, offering small-molecule innovation exposure amid broader biotech funding pressures.

As of: 26.03.2026

Dr. Elena Voss, Biotech Market Analyst: Evotec SE's rebound underscores resilient partnership momentum in a sector facing milestone delays and AI investment headwinds.

Preliminary 2025 Results Spark Initial Selloff

Evotec SE released preliminary full-year 2025 figures on March 18, 2026, reporting group revenue of approximately €820 million. This marked a 5% increase from 2024 but fell below analyst expectations of €850 million. The shortfall stemmed from postponed milestones in key partnerships and weaker fee-for-service revenues in the services unit.

EBIT losses widened to €150 million, driven by higher R&D spending on proprietary programs and AI infrastructure builds. Management guided 2026 revenue to €850-900 million, implying modest growth, while flagging €200 million cash burn tied to AI enhancements. The stock dropped 12% to around €3.88 on Xetra in EUR over the following two days, hitting a 52-week low amid biotech sector concerns.

Yet, by March 25, shares recovered sharply, gaining 5.75% to close at 4.356 EUR on Xetra. This swing reflects investor digestion of the numbers alongside positive partnership updates. Evotec's model as a contract research organization relies heavily on clinical progress from collaborators, making timing critical.

Key Partnerships Fuel Recovery Momentum

On March 19, 2026, Evotec received a $10 million milestone payment from Bristol Myers Squibb as a partnered asset advanced into clinical trials. This cash infusion bolsters liquidity after the results miss. Days later, on March 23, Evotec Biologics was selected by BARDA for antibody optimization in Ebola biomanufacturing, targeting US government needs.

Partnerships accounted for 65% of 2025 revenue via milestones and royalties from deals with BMS, Bayer, and Sanofi. Currently, 18 molecules from collaborations are in clinical stages. A March 20 update confirmed a BMS oncology asset progressing to Phase III, potentially unlocking €300 million in future payments.

These developments counterbalance the revenue shortfalls, reminding investors of Evotec's position as a discovery engine for big pharma. The rebound to 4.356 EUR on Xetra suggests bargain hunting by those betting on milestone catch-up in 2026.

Biotech Sector Volatility Amplifies Moves

Evotec's 5.75% Xetra gain occurs against a choppy biotech backdrop, where funding tightens and clinical risks loom large. Year-to-date, the stock has fallen about 40% on Xetra in EUR, lagging the MDAX index by 25 points. Valuation metrics show a negative P/E of -11.6x for 2025 and EV/Sales of 0.97x, reflecting growth pains.

Cash reserves stood at €350 million end-2025, providing an 18-month runway despite planned burns. Free float is high at 88.77%, with major holders including Excalibur Luxco (9.97%) and Mubadala (6.45%). US names like Vanguard (3.11%) and T. Rowe Price (2.91%) signal transatlantic interest.

Evotec operates from Hamburg, employing around 4,827 staff, with revenue per employee at €0.17 million. Its pipeline targets fibrosis, oncology, infectious diseases, CNS insomnia, chronic cough, and more, blending partnerships with proprietary efforts.

US Investors Gain Indirect Exposure

For US investors, Evotec offers a leveraged play on big pharma pipelines without the binary risks of pure biotech developers. Collaborations with BMS provide entry to small-molecule advances in oncology and beyond. The BARDA deal ties into US biodefense priorities, enhancing relevance.

Traded as EVOTF in US OTC markets, Evotec bridges European discovery expertise with American capital markets. Milestone payments like the recent $10 million from BMS demonstrate tangible value creation. Amid US biotech M&A waves, Evotec's AI-enhanced discovery could attract suitors or deeper alliances.

With €350 million cash, the firm funds AI tools to accelerate hit identification, a trend US hyperscalers and pharma echo. This positions Evotec for US-style tech-biotech convergence, making the 4.356 EUR Xetra level noteworthy for diversified portfolios.

AI Investments and Pipeline Progress

Evotec is ramping AI for drug discovery, contributing to 2025's EBIT losses but promising efficiency gains. This aligns with sector shifts where AI cuts discovery timelines by 30-50% in leading models. Proprietary pipeline includes assets in women's health, nephrology, and antivirals.

Two Phase II setbacks in 2025 deferred €100 million, but the BMS Phase III move offsets this. Evotec Biologics' BARDA selection for antibody cocktails adds manufacturing revenue streams, diversifying from pure discovery. Employee count stabilized at 4,827, supporting scaled operations.

Risks and Open Questions Ahead

Dilution looms if milestones lag, with cash burn projected at €200 million for 2026. Partnership dependency exposes Evotec to partner decisions, as seen in delayed payments. Broader biotech funding crunch could pressure fee-for-service demand.

Proprietary programs carry high failure rates, and AI investments yield uncertain ROI. Year-to-date underperformance flags execution risks. Investors must weigh rebound sustainability against guidance conservatism.

Regulatory hurdles in fibrosis and oncology add uncertainty. US investors face currency swings from EUR exposure and OTC liquidity limits. Monitoring Q1 2026 updates will clarify trajectory.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.